PE20000054A1 - Derivados de 3-piperidil-4-oxoquinazolina y composiciones farmaceuticas que comprenden los mismos - Google Patents
Derivados de 3-piperidil-4-oxoquinazolina y composiciones farmaceuticas que comprenden los mismosInfo
- Publication number
- PE20000054A1 PE20000054A1 PE1998001218A PE00121898A PE20000054A1 PE 20000054 A1 PE20000054 A1 PE 20000054A1 PE 1998001218 A PE1998001218 A PE 1998001218A PE 00121898 A PE00121898 A PE 00121898A PE 20000054 A1 PE20000054 A1 PE 20000054A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidyl
- alkylene
- compound
- pharmaceutical compositions
- compositions including
- Prior art date
Links
- YVXDOICWRFTZHG-UHFFFAOYSA-N 2-piperidin-3-yl-1h-quinazolin-4-one Chemical class N1C2=CC=CC=C2C(=O)N=C1C1CCCNC1 YVXDOICWRFTZHG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 C1-C4 HALOALKYL Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 150000001924 cycloalkanes Chemical class 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003228 microsomal effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN DERIVADO DE 3-PIPERIDIL-4-OXOQUINAZOLINA DE FORMULA I, DONDE R ES -NR1R2; R1 Y R2 SON H, ALQUILO C1-C4, ARALQUILO, BENZOILO, ENTRE OTROS; O R1 Y R2 FORMAN JUNTOS UN COMPUESTO DE FORMULA ii; LOS ANILLO A Y B SON UN GRUPO AROMATICO, HETEROCICLO AROMATICO, CICLOALCANO DE 3-7 MIEMBROS, ENTRE OTROS; X ES UN ENLACE, ALQUILENO C1-C4, ALQUENILENO C2-C4, ENTRE OTROS; Y ES UN ENLACE, ALQUILENO C1-C4, CARBONILO; R3 Y R4 SON H, ALQUILO C1-C4, HALOGENO, HALOALQUILO C1-C4, HIDROXILO, AMINO, NITRO. UN COMPUESTO PREFERIDO ES 3-{1-[2-[N-(2-METILFENIL)-N-FENILAMINO]ETIL]PIPERIDIN-4-IL]-3H-QUINAZOLIN-4-ONA, ENTRE OTROS. EL COMPUESTO I ES UN INHIBIDOR DE LA TRANSFERASA DE TRIGLICERIDOS MICROSOMALES Y PUEDE SER UTIL EN LA PREVENCION Y TRATAMIENTO DE HIPERLIPEMIA O ARTERIOSCLEROSIS, PANCREATITIS, OBESIDAD, HIPERCOLESTEROLEMIA, HIPERTRIGLICERIDEMIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36281997 | 1997-12-12 | ||
| JP10288979A JP2959765B2 (ja) | 1997-12-12 | 1998-10-12 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000054A1 true PE20000054A1 (es) | 2000-02-09 |
Family
ID=26557408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001218A PE20000054A1 (es) | 1997-12-12 | 1998-12-14 | Derivados de 3-piperidil-4-oxoquinazolina y composiciones farmaceuticas que comprenden los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6235730B1 (es) |
| EP (1) | EP0970954A4 (es) |
| JP (1) | JP2959765B2 (es) |
| KR (1) | KR20000070983A (es) |
| CN (1) | CN1252068A (es) |
| AR (1) | AR009212A1 (es) |
| AU (1) | AU717963B2 (es) |
| BR (1) | BR9807339A (es) |
| CA (1) | CA2280705A1 (es) |
| HU (1) | HUP0001154A3 (es) |
| ID (1) | ID23439A (es) |
| IL (1) | IL131319A0 (es) |
| NO (1) | NO993868L (es) |
| NZ (1) | NZ337118A (es) |
| PE (1) | PE20000054A1 (es) |
| SK (1) | SK109399A3 (es) |
| TR (1) | TR199901933T1 (es) |
| WO (1) | WO1999031085A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6767739B2 (en) | 2001-07-30 | 2004-07-27 | Isis Pharmaceuticals Inc. | Antisense modulation of microsomal triglyceride transfer protein expression |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| USPP12295P2 (en) * | 1999-06-01 | 2001-12-18 | Florfis Ag | Geranium plant named ‘Fiscoral’ |
| US6258819B1 (en) * | 1999-08-05 | 2001-07-10 | Syntex (U.S.A.) Llc | Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones |
| JP2003104971A (ja) * | 1999-08-12 | 2003-04-09 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| US6800651B2 (en) | 2000-02-03 | 2004-10-05 | Eli Lilly And Company | Potentiators of glutamate receptors |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| UA75660C2 (en) * | 2001-06-28 | 2006-05-15 | Pfizer Prod Inc | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| WO2003072532A1 (en) | 2002-02-28 | 2003-09-04 | Japan Tobacco Inc. | Ester compound and medicinal use thereof |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
| HRP20090581T1 (hr) * | 2003-10-08 | 2009-12-31 | Eli Lilly And Company | Spojevi i postupci za liječenje dislipidemije |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7378426B2 (en) * | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| MX2007004973A (es) * | 2004-10-25 | 2007-06-14 | Japan Tobacco Inc | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. |
| EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| US8158617B2 (en) | 2006-05-16 | 2012-04-17 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
| AU2007303846B2 (en) * | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
| US8735391B2 (en) * | 2008-09-26 | 2014-05-27 | University Of Kansas | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods |
| US9040533B2 (en) | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
| AU2017311691B2 (en) | 2016-08-18 | 2021-12-02 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1583753A (en) * | 1976-07-14 | 1981-02-04 | Science Union & Cie | Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them |
| US4292321A (en) | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
| US4364954A (en) | 1980-01-10 | 1982-12-21 | Warner-Lambert Company | Diphenylpropanamines, compositions thereof and use thereof |
| CA2091102C (en) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| JPH08151377A (ja) * | 1994-11-25 | 1996-06-11 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
| US5919795A (en) | 1995-06-07 | 1999-07-06 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion |
| DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
-
1998
- 1998-10-12 JP JP10288979A patent/JP2959765B2/ja not_active Expired - Lifetime
- 1998-12-11 AR ARP980106296A patent/AR009212A1/es unknown
- 1998-12-11 SK SK1093-99A patent/SK109399A3/sk unknown
- 1998-12-11 TR TR1999/01933T patent/TR199901933T1/xx unknown
- 1998-12-11 HU HU0001154A patent/HUP0001154A3/hu unknown
- 1998-12-11 CN CN98803899A patent/CN1252068A/zh active Pending
- 1998-12-11 US US09/367,242 patent/US6235730B1/en not_active Expired - Fee Related
- 1998-12-11 IL IL13131998A patent/IL131319A0/xx unknown
- 1998-12-11 CA CA002280705A patent/CA2280705A1/en not_active Abandoned
- 1998-12-11 AU AU15068/99A patent/AU717963B2/en not_active Ceased
- 1998-12-11 WO PCT/JP1998/005628 patent/WO1999031085A1/ja not_active Ceased
- 1998-12-11 EP EP98959187A patent/EP0970954A4/en not_active Withdrawn
- 1998-12-11 KR KR1019997007249A patent/KR20000070983A/ko not_active Ceased
- 1998-12-11 BR BR9807339A patent/BR9807339A/pt not_active IP Right Cessation
- 1998-12-11 ID IDW991010A patent/ID23439A/id unknown
- 1998-12-11 NZ NZ337118A patent/NZ337118A/xx unknown
- 1998-12-14 PE PE1998001218A patent/PE20000054A1/es not_active Application Discontinuation
-
1999
- 1999-08-11 NO NO993868A patent/NO993868L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR009212A1 (es) | 2000-04-12 |
| IL131319A0 (en) | 2001-01-28 |
| EP0970954A1 (en) | 2000-01-12 |
| JP2959765B2 (ja) | 1999-10-06 |
| AU1506899A (en) | 1999-07-05 |
| NO993868D0 (no) | 1999-08-11 |
| EP0970954A4 (en) | 2001-01-10 |
| WO1999031085A1 (en) | 1999-06-24 |
| CA2280705A1 (en) | 1999-06-24 |
| ID23439A (id) | 2000-04-20 |
| HUP0001154A3 (en) | 2001-06-28 |
| TR199901933T1 (xx) | 2000-03-21 |
| AU717963B2 (en) | 2000-04-06 |
| JPH11228569A (ja) | 1999-08-24 |
| KR20000070983A (ko) | 2000-11-25 |
| US6235730B1 (en) | 2001-05-22 |
| NZ337118A (en) | 2000-03-27 |
| HUP0001154A2 (hu) | 2001-04-28 |
| SK109399A3 (en) | 2000-01-18 |
| BR9807339A (pt) | 2000-03-21 |
| NO993868L (no) | 1999-10-12 |
| CN1252068A (zh) | 2000-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000054A1 (es) | Derivados de 3-piperidil-4-oxoquinazolina y composiciones farmaceuticas que comprenden los mismos | |
| ATE513813T1 (de) | Cyclische amidderivate und deren herstellung und verwendung als antithrombosemittel | |
| MX9202142A (es) | Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende. | |
| UY26943A1 (es) | Derivados de piridina | |
| EP0628311A4 (en) | ANTIDEPRESSOR. | |
| FI946083A0 (fi) | Antianginaaliset purinonit | |
| ATE355282T1 (de) | Biologisch aktive derivate des methylenblaus | |
| EP0638567A4 (en) | ADENOSINE INHIBITORS. | |
| HRP20020182B1 (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
| DK0669968T3 (da) | Aniliner som mærkningsmidler til mineralolier | |
| YU17092A (sh) | Derivati 2,4-diaminohinazolina | |
| NO932607L (no) | Piperidinderivater og anvendelse av disse | |
| ATE224392T1 (de) | Kondensierte tropanderivate als neurotransmitter- reuptake-inhibitoren | |
| ATE481387T1 (de) | Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| CO4290355A1 (es) | Derivados de indol | |
| ES2086341T3 (es) | Derivados de aminoacidos con propiedades inhibidoras de la renina, procedimiento para su preparacion, agentes que los contienen y su utilizacion. | |
| CO4970840A1 (es) | Ciertas 1-(2-naftil) y 1-(azanaftil)-4-(1-fenilmetil) pipe- razinas; ligandos especificos del subtipo receptor de la dopamina | |
| CO4810374A1 (es) | Nueva utilizacion de compuestos para actividad anti- pruritica | |
| NO973857D0 (no) | 1-aryl-2-acylamino-etanforbindelser og deres anvnedelse som neurokinin-, spesielt neurokinin-1-antagonister | |
| UY25211A1 (es) | Inhibidores de isoquinolinilguanidina uroquinasa | |
| MX9400253A (es) | Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| EA199900374A1 (ru) | Ингибитор вторичной катаракты | |
| NO972938L (no) | Farmasöytiske piperazinforbindelser | |
| ATE281433T1 (de) | Substituierte pyrrolidine als inhibitoren der zelladhäsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |